Wednesday, May 13, 2026 12:45:56 AM
I do enjoy the buzzing of the board anytime we have a decent increase of SP. But during this time of excitement, I feel like a lot of nonsense and FUD narratives come up - First of all, NWBO doesn’t care and shouldn’t care about this board and its opinions. Their only goal should be MHRA approval, starting P1/P2 Direct Trials, and pursuing partnerships that can help them expand faster while keeping afloat. Because THAT is what is going to affect Share Price which is what WE want.
900 Millions Shares - I hope this would be used for partnerships but quite frankly, NWBO does not have revenue to sustain business operations JUST LIKE EVERY OTHER pre-revenue biotech company. Thats why they either get bought up or their SP rockets up when there is market approval. Any LONG should be able to recognize that this company needs cash to stay afloat and dilution SHOULD BE EXPECTED. Even if the company dilutes shares, they should at higher SP when they can because last time I checked, no one can predict future SP and approval date even though so many people on this board attempt to do so.
Risk/Reward - Besides MM influences, synthetic shorts, (any additional reason you want to put in) - there is a reason why the SP is also not as high. NWBO either makes or breaks with this MHRA approval. Granted, I think with the 900 ASM increase in shares, they have a little more of a runway but if MHRA does not approve - I would imagine SP would lower but I have no idea where. This is a HIGH risk biotech play - granted, I personally think all of the signs point to Approval (NICE, Parliament Involvement, Special Program, Data from Long Tail Survival) but company hiring or C-Labs is EXPECTED. For example, CVM was hiring and doing similar things to NWBO before their application was rejected. I am just stating that NWBO does not KNOW for certain if they are getting approved, but SHOULD proceed as if they are getting approval b/c if they don’t - we are ALL screwed.
Share Price (Up/Down) - Honestly, I stopped giving a crap about 20/30% increase or decreases in SP. Recall, we were at a .35 high a few months ago? - it DOESN’T MATTER. It COULD be MHRA Approval, Cancord, Big Retail Players, etc. BUT NOBODY KNOWS FOR CERTAIN. All are just basely theories that you won’t be able to confirm until after news comes out anyway. I am IN THIS FOR THE LONG HAUL - till we get off the OTC, DIRECT is being used for ALL SOLID TUMORS, and when the ENTIRE world knows about NWBO and DC VACCINES. (I will sell a portion at $10+ though b/c my parents did not plan for retirement haha).
TLDR: NWBO needs to dilute shares during higher SP b/c they do not when approval is coming and THEY SHOULD DO IT. MHRA Approval makes and breaks the company (I think almost 90%+ chance of approval, but rejection is devastating in this case). SP increases could be a sign of approval but could be a multitude of other factors that you won’t know till after the news comes out. That's the rub in my perspective EVERYTHING else is noise. P.S. - I will also try to post in Danish Dudes NWBO forum/website - it looks really nice.
900 Millions Shares - I hope this would be used for partnerships but quite frankly, NWBO does not have revenue to sustain business operations JUST LIKE EVERY OTHER pre-revenue biotech company. Thats why they either get bought up or their SP rockets up when there is market approval. Any LONG should be able to recognize that this company needs cash to stay afloat and dilution SHOULD BE EXPECTED. Even if the company dilutes shares, they should at higher SP when they can because last time I checked, no one can predict future SP and approval date even though so many people on this board attempt to do so.
Risk/Reward - Besides MM influences, synthetic shorts, (any additional reason you want to put in) - there is a reason why the SP is also not as high. NWBO either makes or breaks with this MHRA approval. Granted, I think with the 900 ASM increase in shares, they have a little more of a runway but if MHRA does not approve - I would imagine SP would lower but I have no idea where. This is a HIGH risk biotech play - granted, I personally think all of the signs point to Approval (NICE, Parliament Involvement, Special Program, Data from Long Tail Survival) but company hiring or C-Labs is EXPECTED. For example, CVM was hiring and doing similar things to NWBO before their application was rejected. I am just stating that NWBO does not KNOW for certain if they are getting approved, but SHOULD proceed as if they are getting approval b/c if they don’t - we are ALL screwed.
Share Price (Up/Down) - Honestly, I stopped giving a crap about 20/30% increase or decreases in SP. Recall, we were at a .35 high a few months ago? - it DOESN’T MATTER. It COULD be MHRA Approval, Cancord, Big Retail Players, etc. BUT NOBODY KNOWS FOR CERTAIN. All are just basely theories that you won’t be able to confirm until after news comes out anyway. I am IN THIS FOR THE LONG HAUL - till we get off the OTC, DIRECT is being used for ALL SOLID TUMORS, and when the ENTIRE world knows about NWBO and DC VACCINES. (I will sell a portion at $10+ though b/c my parents did not plan for retirement haha).
TLDR: NWBO needs to dilute shares during higher SP b/c they do not when approval is coming and THEY SHOULD DO IT. MHRA Approval makes and breaks the company (I think almost 90%+ chance of approval, but rejection is devastating in this case). SP increases could be a sign of approval but could be a multitude of other factors that you won’t know till after the news comes out. That's the rub in my perspective EVERYTHING else is noise. P.S. - I will also try to post in Danish Dudes NWBO forum/website - it looks really nice.
Bullish
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
